IPF pathogenesis is dependent upon TGFβ induction of IGF-1

Area of Science:

• Pulmonary Medicine
• Fibrotic Diseases
• Molecular Biology

Background:

• Pathogenic fibrotic diseases like idiopathic pulmonary fibrosis (IPF) have poor prognoses and limited treatment options.
• Transforming Growth Factor Beta (TGFβ) and insulin-like growth factor-1 (IGF-1) are implicated in fibrosis, but IGF-1's specific role in myofibroblasts during TGFβ-induced fibrogenesis and IPF is unclear.

Purpose of the Study:

• To investigate the upregulation of IGF-1 by TGFβ in myofibroblasts and its role in IPF.
• To identify the molecular mechanisms mediating TGFβ-induced IGF-1 expression.
• To evaluate the therapeutic potential of targeting the IGF-1 pathway in lung fibrosis.

Main Methods:

• Documented IGF-1 upregulation via TGFβ in myofibroblasts and fibrotic lung tissue.
• Identified the IGF-1 C1 promoter's role in TGFβ-induced transcription.
• Utilized SMAD2 and mTOR signaling pathway analysis.
• Assessed IGF-1 receptor (IGF-1R) activation in myofibroblast function.
• Tested the efficacy of the IGF-1R inhibitor OSI-906 in a murine lung fibrosis model.

Main Results:

• TGFβ upregulates IGF-1 in myofibroblasts and fibrotic lung tissue, correlating with reduced pulmonary function in IPF patients.
• TGFβ increases IGF-1 transcription via the C1 promoter in pulmonary fibroblasts.
• SMAD2 and mTOR signaling are essential for TGFβ-dependent IGF-1 expression.
• IGF-1R activation is critical for TGFβ-driven myofibroblast activity and excessive wound healing.
• IGF-1R inhibition with OSI-906 effectively slowed murine lung fibrosis progression.

Conclusions:

• IGF-1 acts as a novel fibrotic-switch, significantly contributing to TGFβ-induced fibrogenesis and IPF.
• Targeting the IGF-1R pathway presents a promising therapeutic strategy for treating fibrotic lung diseases.
• Further understanding of IGF-1's role advances the development of effective therapies for debilitating fibrotic conditions.